Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group)

BACKGROUND: Oesophageal and gastrooesophageal junction (GOJ) carcinoma frequently present with dysphagia and de novo metastatic disease. There is scope to improve treatment paradigms to both address symptoms and improve survival. One method is integrating immune checkpoint inhibition with novel trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Day, Fiona, Sridharan, Swetha, Lynam, James, Gedye, Craig, Johnson, Catherine, Fraser, Allison, Thompson, Stephen R., Michael, Michael, Leong, Trevor, Roy, Amitesh, Kumar, Mahesh, van der Westhuizen, Andre, Quah, Gaik T., Mandaliya, Hiren, Mallesara, Girish, Sappiatzer, Joshua, Oldmeadow, Christopher, Martin, Jarad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758808/
https://www.ncbi.nlm.nih.gov/pubmed/36528772
http://dx.doi.org/10.1186/s12885-022-10407-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758808/
https://www.ncbi.nlm.nih.gov/pubmed/36528772
http://dx.doi.org/10.1186/s12885-022-10407-8

Ejemplares similares